Searchable abstracts of presentations at key conferences in endocrinology

ea0029p48 | Adrenal cortex | ICEECE2012

MicroRNA profiling of benign and malignant adrenocortical tumors reveals potential biomarkers of recurrence

Chabre O. , Assie G. , Libe R. , Bertherat J. , Feige J. , Cherradi N.

Objective: To identify miRNAs predictors of poor prognosis in adrenocortical cancer.Methods: Using microarrays, we evaluated the expression of 728 human miRNAs in six adenomas (ACAs) and twelve carcinomas (ACCs). The ACC group was composed of two subgroups A and B consisting of six recurrent (subgroup A) and six non-recurrent tumors (subgroup B). These two distinct subgroups have been characterized recently (de Reynies et al, 2009) on the basis of distin...

ea0041gp55 | Cardiovascular endocrinology | ECE2016

IGF-1: A marker of cardio-metabolic risk in obstructive sleep apnea (OSA) syndrome?

Pepin JL , Galerneau LM , Borel AL , Chabre O , Sapene M , Stach B , Girey-Rannaud J , Tamisier R , Caron Ph

Introduction: Insulin-like growth factor-1 (IGF-I), the main growth factor associated with GH secretion, directly opposes endothelial dysfunction and limit early atherosclerosis by favoring nitric oxide production, promoting insulin sensitivity and preventing postprandial dyslipidemia. A low serum IGF-I level has been reported in patients with OSA syndrome and might be one of the mechanisms underlying cardio-metabolic risks in OSA patients. IGF-1 levels were evaluated in a lar...

ea0041gp157 | Pituitary - Clinical | ECE2016

Prevalence of acromegaly in patients referred for sleep apnea syndrome (SAS): results of ACROSAS Study

Pepin J L , Galerneau L M , Borel A L , Chabre O , Sapene M , Stach B , Girey-Rannaud J , Tamisier R , Caron Ph

Introduction: Acromegaly is a rare disease (estimated prevalence 40–125 cases per million) resulting from GH/IGF1 hypersecretion, mostly by pituitary adenomas. SAS has a prevalence of up to 80% in acromegalic patients. The high frequency of acromegaly-related comorbidities and delayed diagnosis although effective treatments exist, make it necessary a screening of acromegaly in at risk populations.Aim: In a national multicenter study, to determine th...

ea0026p251 | Pituitary | ECE2011

Lost to follow-up in acromegaly, results of ACROSPECT observational study

Delemer B D , Reines C R , Brue T B , Rudelli C C Cortet , Raingeard I R , Reznik Y R , Parot X P , Chabre O C

Lost to follow-up (LTFU) is a frequent problem in chronic diseases not evaluated yet in acromegaly despite the long-term need of medical treatment and complications survey in this disease.Objectives: Evaluation of the prevalence of LTFU patients in a multi-center cohort, characteristics of defaulters and description of their evolution after they have been searched and found.Méthods: Observational multicentric (25 centers study...

ea0026p252 | Pituitary | ECE2011

Initial management and complications of Cushing disease (CD): a French multicenter study of 437 patients

Baudry C , Martinie M , Fathallah-Sahnoun M , Gatta-Cherifi B , Khalil R Bou , Guignat L , Gay E , Raverot G , Brue T , Tabarin A , Chabre O , Bertherat J

Introduction: CD is a rare disease. Our aim was to describe demographic and clinical characteristics together with initial management of patients with CD.Patients and methods: A retrospective analysis of 437 CD patients diagnosed between 1996 and 2009, followed in 5 tertiary centers (Bordeaux, Grenoble, Lyon, Marseille, Paris) was performed in the frame of the national program for rare diseases.Results: 347 (80%) were women. Mean a...

ea0029p993 | Growth hormone IGF axis - basic | ICEECE2012

Clinical characteristics and outcome of acromegaly induced by ectopic secretion of GHRH: a French nationwide series of 21 cases

Garby L. , Caron P. , Claustrat F. , Chanson P. , Tabarin A. , Rohmer V. , Arnault G. , Bonnet F. , Chabre O. , Christin Maitre S. , Du Boullay H. , Murat A. , Nakib I. , Sadoul J. , Sassolas G. , Claustrat B. , Raverot G. , Borson Chazot F.

Context: Ectopic GHRH secretion is a rare cause of acromegaly described mainly in isolated case reports.Setting: From the registry of the sole laboratory performing plasma GHRH assays in France, we identified cases of ectopic GHRH secretion presenting with acromegaly between 1983 and 2008.Patients: In total, 21 patients aged 14–77 years, from 12 French hospitals. Median GHRH was 548 ng/l (270–9779)....

ea0026p30 | Adrenal cortex | ECE2011

Is plasma mitotane level >30 mg/l a serious adverse event in patients with adrenocortical carcinoma (ACC)?: a retrospective analysis of the French COMETE network

Mauclere-Denost S M D , Tabarin A T , Drui D D , Chaillous L C , Salenave S S , Leboulleux S L , Chabre O C , Do-Cao C D C , Dubourg H D , Cuvelier M L C , Young J Y , Baudin E B

Background: Mitotane antitumor efficacy is related to plasma levels. Objective responses have been associated with mitotane plasma levels >14 mg/l. However, high plasma levels >20 or >30 mg/l are at higher risk of toxicity, especially neurotoxicity. National-based survey is lacking to evaluate the frequency and severity of high mitotane plasma levels. Our aim was to retrospectively describe serious adverse events (SAE).Methods: Mitotane plasm...

ea0014p559 | (1) | ECE2007

Development and validation of a questionnaire to evaluate health-related quality of life in patients with Cushing’s syndrome

Webb Susan M , Badia Xavier , Barahona Maria- Jose , Colao Annamaria , Strasburger Christian J , Tabarin Antoine , Aken MO van , Pivonello Rosario , Stalla Gunther , Chabre O , Lamberts Steven WJ , Glusman Joan E

Chronic exposure to hypercortisolism has a significant impact on patient’s health and Health-Related Quality of Life (HRQoL), as demonstrated with generic questionnaires. Objective: Develop and validate a disease-generated questionnaire to evaluate HRQoL in patients with Cushing’s syndrome-CS- (Cushing QoL). Methods: After a literature review, interviews with expert endocrinologists and 10 patients identified HRQoL domains and clinical aspects of the disease; an anal...